Full-Time

Director – CMC Biologics

Posted on 9/10/2025

Calico Labs

Calico Labs

201-500 employees

Biopharmaceutical research on aging therapies

Compensation Overview

$245k - $260k/yr

+ Two annual cash bonuses

San Bruno, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Risk Management
Requirements
  • Ph.D. in Biochemistry, Chemical Engineering, Pharmaceutical Sciences, or a related scientific discipline
  • Minimum of 10+ years of progressive experience in CMC development for biologic products within the biopharmaceutical industry
  • Minimum of 5+ years in a leadership or senior scientific role
  • Demonstrated expertise in advancing biologic programs from IND submission through BLA/MAA approval and commercial launch
  • Extensive hands-on experience and leadership in subcutaneous formulation development for biologics
  • Proven experience managing CDMOs for drug substance and drug product manufacturing
  • In-depth knowledge of biologics drug development, including upstream and downstream processing, purification, and aseptic fill/finish
  • Strong expertise in protein chemistry, biophysical characterization, and stability assessment
  • Comprehensive understanding of global GMP regulations (FDA, EMA, ICH) for biologics
  • Proficiency in analytical method development and validation for biologics
  • Familiarity with regulatory requirements for biologics CMC sections in global submissions
  • Exceptional leadership, communication, and interpersonal skills, with the ability to influence and collaborate effectively with diverse stakeholders
  • Proven strategic thinking, problem-solving, and decision-making abilities in a complex and dynamic environment
  • Strong project management skills, capable of managing multiple priorities and delivering results
  • Detail-oriented with a strong commitment to quality and scientific rigor
  • Adaptable and able to work effectively in a fast-paced, evolving organization
  • Must be willing to work onsite at least 4 days a week
Responsibilities
  • Develop and execute comprehensive CMC strategies for biologic programs, from IND-enabling activities through clinical development, regulatory submission, and commercialization
  • Provide expert leadership and oversight for the development of stable, manufacturable, and patient-friendly biologic formulations, with a specific focus on subcutaneous delivery methods
  • Guide and oversee drug substance and drug product process development, manufacturing, and scale-up activities at Contract Development and Manufacturing Organizations
  • Oversee the development and qualification of analytical methods for characterization, release, and stability testing of biologic drug substances and drug products
  • Lead the preparation and authoring of CMC sections for regulatory filings (e.g., INDs, BLAs, MAAs), ensuring compliance with global regulatory requirements
  • Identify, qualify, and manage CDMOs and other third-party vendors for all CMC-related activities, ensuring high-quality execution and adherence to timelines and budget
  • Serve as the primary CMC lead on cross-functional project teams, collaborating closely with Research, Clinical, Regulatory Affairs, Quality Assurance, and Commercial teams
  • Proactively identify CMC-related risks and develop robust mitigation strategies to ensure program success and uninterrupted supply
  • Ensure all CMC activities comply with global Good Manufacturing Practice and relevant regulatory guidelines
  • Oversee successful technology transfer activities between internal teams and CDMOs, and between different manufacturing sites
  • Contribute to and manage CMC project budgets, identifying opportunities for efficiency

Calico Labs conducts research to understand aging biology and develops treatments for age-related diseases in the biopharmaceutical space. It uses basic and translational science with advanced technologies and collaborations with universities and other pharma companies to study aging mechanisms and translate discoveries into therapies. Its main value comes from partnerships, shared intellectual property, and co-development of new therapies funded by grants and research contracts, rather than selling products directly from its own labs. The goal is to slow or prevent diseases linked to aging by turning biological insights into real-world therapies, leveraging a network of researchers and industry partners to accelerate progress.

Company Size

201-500

Company Stage

Seed

Total Funding

$2M

Headquarters

South San Francisco, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Extended Broad Institute collaboration to 2029 focuses on neurodegeneration.
  • FDA START Pilot selects fosigotifator, accelerating VWM disease development.
  • Michael Lenardo appointed CSO in August 2024, enhancing immunology expertise.

What critics are saying

  • AbbVie exits $3.5B alliance, eliminating commercialization for ABBV-CLS-484.
  • Fosigotifator fails ALS endpoint, invalidating eIF2B strategy across pipeline.
  • Alphabet cuts funding by 2027 without Phase 3 candidate, redirecting to Verily.

What makes Calico Labs unique

  • Calico targets novel aging biology like ISR with fosigotifator for neurodegeneration.
  • Portfolio exceeds 20 preclinical compounds in cancer and neurological diseases.
  • Pioneers first-in-class PTPN2/N1 inhibitor ABBV-CLS-484 for immunotherapy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Professional Development Budget

Company News

pharmaphorum
Nov 13th, 2025
AbbVie exits alliance with Alphabet biotech Calico; report

AbbVie exits alliance with Alphabet biotech Calico; report. Reports are emerging that a multibillion-dollar partnership between AbbVie and Alphabet-backed biotech Calico has come to an end after more than a decade. The divorce - first report by Stat - comes just a few days after Calico issued a press release that celebrated the FDA award of orphan drug status to ABBV-CLS-628, an AbbVie-partnered programme in phase 2 testing for autosomal dominant polycystic kidney disease (ADPKD) that has also been fast-tracked by the US regulator. The alliance between AbbVie and Calico dates back to 2014, just a year after it was launched by Alphabet's Google unit, when the two companies pledged up to $1.5 billion to a joint effort to develop treatments for age-related diseases, including neurodegenerative disorders and cancer. It was expanded in 2018 and again in 2021 to a potential value of $3.5 billion, with Calico responsible for taking projects into early clinical development until 2025 and running phase 2a trials until 2030, with AbbVie having an option to take over projects once they reach later-stage development and to lead commercial activities. However, after more than 11 years and an investment of more than $1.75 billion, the partners have yet to score a regulatory approval for a new medicine. Just last month, Calico appointed AbbVie's former head of global medicinal chemistry, Philip Kym, for the newly created role of head of drug discovery, in a further sign of how closely the two companies have been working. According to Stat, AbbVie's change of heart - revealed in a series of internal emails - is a result of shift in strategy at the pharma group away from small-molecule drugs and towards more complex genetic medicines and will lead to around 100 employees losing their jobs. AbbVie has not commented on the status of its relationship with Calico. If confirmed, the separation also follows disappointing results with another AbbVie-partnered programme - fosigotifator (ABBV-CLS-7262) for amyotrophic lateral sclerosis (ALS) - earlier this year. Data from an arm of the HEALEY ALS Platform Trial found no evidence for any impact on ALS disease progression with fosigotifator, an eIF2B activator, as well as secondary measures like ALS symptoms, respiratory function, and quality-of-life scores. Other partnered projects include ABBV-CLS-484, a PTN1/2 inhibitor in early-stage clinical testing as a potential cancer immunotherapy. Meanwhile, a recent decision to in-license an antibody-based IL-11 inhibitor (9MW3811) for fibrotic diseases from China's Mabwell Bioscience, rather than continue to rely on its in-house discovery engine, has also been viewed in some quarters as a sign that Calico has not been firing on all cylinders.

BioSpace
Jun 27th, 2025
Alphabet Subsidiary Calico Colors In Up To $570M+ Aging Deal With China's Mabwell

Alphabet's aging-focused subsidiary Calico Life Sciences has entered into an exclusive licensing agreement with Mabwell Bioscience to advance the Shanghai biotech's anti-IL-11 monoclonal antibodies for age-related diseases.

Fierce Biotech
Jun 26th, 2025
Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset

According to the agreement, Calico will have exclusive rights to develop and commercialize 9MW3811 in all regions except greater China.

PR Newswire
Jun 7th, 2024
Calico Life Sciences Announces That Fosigotifator (Abbv-Cls-7262) For Vanishing White Matter Disease Has Been Selected For The Fda Start Pilot Program

SOUTH SAN FRANCISCO, Calif., June 7, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced that its investigational eIF2B activator fosigotifator (ABBV-CLS-7262) has been accepted into the U.S. Food and Drug Administration (FDA) Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program. Fosigotifator is being developed by Calico and AbbVie pursuant to their 2014 collaboration as a potential treatment for Vanishing White Matter (VWM) disease.FDA's Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) initiated the START Pilot Program to help further accelerate the development of novel drug and biological products for rare diseases. Selected participants will be able to obtain frequent advice and enhanced communication with FDA review staff to address program-specific development issues, including, but not limited, to clinical study design, choice of control group, and fine-tuning the choice of patient population."Calico is honored that fosigotifator has been selected by CDER as one of three candidates for the FDA's innovative START Pilot Program. The inclusion of fosigotifator underscores the potential of this investigational therapy in addressing the unmet needs of individuals and families affected by Vanishing White Matter Disease," said Arthur D

PR Newswire
May 9th, 2024
Calico And Broad Institute Extend Collaboration Adding Focus On Age-Related Neurodegeneration

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico) and the Broad Institute of MIT and Harvard, announced today that the two organizations have further extended their partnership with an added focus on age-related neurodegeneration. Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery. Terms of the agreement were not disclosed."We are pleased to continue our collaboration with the Broad Institute. It is entering its tenth year and we've made a considerable amount of progress, including discoveries that could make immunotherapies more effective for more patients. We are currently testing this approach in two early-stage clinical trials evaluating a pair of PTPN2 inhibitors," said Arthur D

INACTIVE